COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 22 for:    Recruiting, Enrolling by invitation Studies | Interventional Studies | glioma | United States | Start date from 08/08/2019 to 12/19/2019

Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma (FACBC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04114370
Recruitment Status : Recruiting
First Posted : October 3, 2019
Last Update Posted : November 4, 2020
Sponsor:
Collaborator:
Blue Earth Diagnostics
Information provided by (Responsible Party):
James Mountz, University of Pittsburgh

Brief Summary:
This is a pilot study to assess the ability of [F-18]fluciclovine to differentiate pseudoprogression from progression in participants after therapy, at imaging time points within the 12 week interval post chemoradiation. [F-18]fluciclovine. PET will be obtained at the time point in the 12 week interval in which MRI demonstrates increase in enhancing volume with the differential diagnosis of pseudoprogression versus tumor progression. At the same time point (at least 6 hours after [F-18]fluciclovine or up to 3 days) F-18 FDG will also be performed consistent with standard clinical practice. The verification of pseudoprogression versus tumor progression will be determined by the regression of enhancing lesion on subsequent MRI imaging obtained as part of standard care.

Condition or disease Intervention/treatment Phase
Glioma Drug: 18F-fluciclovine Early Phase 1

Detailed Description:

In this pilot study the investigators propose to image 10 participants who have been previously diagnosed by resection or biopsy with grade 3 or 4 glioma.

All glioma cases undergoing resection at UPMC are evaluated by immunohistochemistry for mutations in p53, nuclear localization of ATRX, and the presence of IDH1R132H mutation as part of standard neuropathologic integrated diagnosis using the WHO 2016 diagnostic criteria. All glioma cases resected at UPMC undergo genetic profiling using next generation sequencing.

MRI imaging will be obtained as part of standard clinical care. The MRI sequences include T1 pre and post contrast, T2 FLAIR, DWI, ADC and perfusion sequences using the imaging algorithm for evaluating treatment response in glioma treatment trials. Radiogenomic analysis will be performed using the MRI imaging sequences obtained as standard clinical care.

Layout table for study information
Study Type : Interventional
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma
Actual Study Start Date : October 22, 2019
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : September 30, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Participants with Glioma
[F18]fluciclovine will be utilized to assess tumor viability compared with F-18 FDG PET or diagnostic MRI.
Drug: 18F-fluciclovine
Prior to beginning PET imaging, 18F-fluciclovine will be administered as an intravenous bolus injection followed by a 10mL saline flush. 18F-fluciclovine will be injected through a cannula (or indwelling catheter) in an antecubital vein or another vein that will provide access. The administration site will be evaluated pre- and post-administration for any reaction. Documentation of administration to a participant will be recorded or as part of the scan upload, including date, prescription number, dose activity (as measured at time of administration), total volume, and start/stop time of administration.




Primary Outcome Measures :
  1. To assess the ability of [F-18]fluciclovine to differentiate radionecrosis (pseudoprogression) from tumor recurrence (progression) in patients after therapy, at imaging time points within the 12 week interval post chemoradiation. [ Time Frame: 90 minutes ]
    To assess the ability of [F-18]fluciclovine to differentiate pseudoprogression from progression as compared to F-18 FDG, regions of interest will be drawn around MRI anatomically defined enhancing tumor regions and translated to both the F-18 FDG and F-18 fluciclovine PET scans to obtain SUV for each tracer. The SUV values will be correlated with the diagnosis of pseudoprogression versus tumor progression as determined by the regression of lesion enhancement on subsequent standard clinical follow up MRI imaging, as described in the protocol.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. Age ≥ 18 years old.

    2. Been previously diagnosed by resection or biopsy with grade 3 or 4 glioma.

    3. Agree to use adequate contraception as indicated in this protocol.

    4. Consent to PET scanning and receipt of one injection of 18F-fluciclovine.

    5. Able to comply with study procedures.

    6. Able to give written consent.

    7. Subject has had a standard of care, diagnostic MRI study which was indeterminate due to the inability to differentiate pseudoprogression versus tumor progression.

Exclusion Criteria:

  • 1. Are a pregnant or breastfeeding female.

    2. Are participating in a clinical trial of another unlicensed product.

    3. Are undergoing 18F-fluciclovine PET for reason(s) other than newly diagnosed or recurrent glioma.

    4. Have a hypersensitivity to 18F-fluciclovine.

    5. Have acute renal failure or moderate/severe renal impairment, according to local clinical guidelines.

    6. Have a non-MRI compatible implantable device or another contraindication for MRI scan.

    7. Are deemed ineligible to participate for other reasons by an investigator.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04114370


Contacts
Layout table for location contacts
Contact: James Mountz, MD, PhD 412-647-0104 mountzjm@upmc.edu
Contact: Frank Lieberman, MD liebermanf@upmc.edu

Locations
Layout table for location information
United States, Pennsylvania
UPMC Hospitals Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
James Mountz
Blue Earth Diagnostics
Investigators
Layout table for investigator information
Principal Investigator: James M Mountz, MD University of Pittsburgh
Layout table for additonal information
Responsible Party: James Mountz, Professor, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT04114370    
Other Study ID Numbers: STUDY19010216
First Posted: October 3, 2019    Key Record Dates
Last Update Posted: November 4, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue